Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

44.81 +0.69 (+1.56%)

Streaming Delayed Price Updated: 1:52 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 Next >

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

Via PredictStreet

Topics Economy Intellectual Property

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast ↗

August 08, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

What to Expect from Xenon Pharmaceuticals's Earnings ↗

May 09, 2025

Via Benzinga

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Preview: Xenon Pharmaceuticals ↗

November 11, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

February 28, 2024

Via Benzinga

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

December 08, 2023

Via Benzinga

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

Crude Oil Gains 3%; US Inflation Eases In April ↗

May 13, 2025

Via Benzinga

Topics Economy

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

May 07, 2025

Via Benzinga

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 07, 2025

Via Benzinga

XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 ↗

August 08, 2024

XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 ↗

May 09, 2024

XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.